Amgen, Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Amgen, Inc. (NASDAQ AMGN) traded up $2.47 during mid-day trading on Wednesday, reaching $188.01. 4,009,525 shares of the company’s stock traded hands, compared to its average volume of 2,700,000. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $136,480.00, a price-to-earnings ratio of 16.98, a PEG ratio of 2.70 and a beta of 1.36. Amgen, Inc. has a one year low of $150.38 and a one year high of $191.10.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. Amgen’s revenue was down .7% compared to the same quarter last year. During the same quarter last year, the firm posted $3.02 earnings per share. sell-side analysts anticipate that Amgen, Inc. will post 12.71 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.81%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is 41.55%.
Amgen declared that its Board of Directors has authorized a stock buyback program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.
Hedge funds have recently made changes to their positions in the business. Berkshire Asset Management LLC PA boosted its stake in shares of Amgen by 8.6% in the fourth quarter. Berkshire Asset Management LLC PA now owns 127,873 shares of the medical research company’s stock valued at $22,237,000 after purchasing an additional 10,162 shares during the period. Charter Trust Co. boosted its stake in shares of Amgen by 10.5% in the fourth quarter. Charter Trust Co. now owns 12,026 shares of the medical research company’s stock valued at $2,092,000 after purchasing an additional 1,141 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of Amgen by 3.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,304,340 shares of the medical research company’s stock valued at $574,680,000 after purchasing an additional 123,250 shares during the period. Burns J W & Co. Inc. NY boosted its stake in shares of Amgen by 2.9% in the fourth quarter. Burns J W & Co. Inc. NY now owns 19,918 shares of the medical research company’s stock valued at $3,464,000 after purchasing an additional 558 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of Amgen by 27.6% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 20,142 shares of the medical research company’s stock valued at $3,503,000 after purchasing an additional 4,360 shares during the period. 78.48% of the stock is owned by institutional investors.
Several equities research analysts recently issued reports on the stock. Bank of America raised their price objective on shares of Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday, October 5th. Oppenheimer restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. Mizuho restated a “buy” rating and set a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley restated an “overweight” rating and set a $196.00 price objective (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, Cann restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $190.15.
TRADEMARK VIOLATION WARNING: “Amgen, Inc. (AMGN) EVP Sean E. Harper Sells 1,525 Shares” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2018/01/17/amgen-inc-amgn-evp-sean-e-harper-sells-1525-shares-2.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.